Online registration is closed but if you would like to attend please contact alicia@onenucleus.com

Much has been written and debated over recent months about the dangers of concussion incurred playing contact sports such as football, rugby and American Football. Some suggesting it will compromise the attraction of the game to future players, others suggesting it could see financial ruin for some sports, but for most running these games an opportunity to show how far they can adapt the rules to increase safety and player wellbeing.  After seeing the investment into stopping the spread of Covid and while there is a sentiment among the City, can impact investing in Life Sciences be a strong lever for progress in this area?  Equally, sentiment may also be negative if track records are not good. 

This session will discuss what R&D is happening to treat the effects of concussions, how new technologies are allowing better diagnoses and monitoring and ultimately whether there is a case for investing in new medicines to treat the resultant disorders.

Panel
Mike Ward, Global Head of Thought Leadership, Clarivate (Moderator)
Michael Wyand, CEO, Oxeia Biopharmaceuticals, Inc
Hugh Nuthall, Senior Director, Search & Evaluation Neuroscience, Eli Lilly and Company
Claire Thompson, CEO, Agility Life Sciences
Eva Haas, IR Consultant, Optimum Strategic Communications
Will Walker-Arnott, Senior Investment Manager, Charles Stanley & Co. Limited

Prices

One Nucleus members: Free

Non-Members: £50 + VAT

Academics: please contact alicia@onenucleus.com